Simcere Zaiming is an oncology-focused bipharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Limited . Founded in 2023, Simcere Zaiming is dedicated to developing ground breaking therapies to meet the unmet clinical needs of cancer patients globally. With a robust and innovative R&D pipeline featuring distinct clinical assets, Simcere Zaiming has successfully launched several innovative products in China, including Enzeshu, COSELA, Enweida, Endosta, and Enlituo. The company is determined to deliver potentially transformative treatment options to cancer patients worldwide through its R&D, manufacturing, and commercialization capabilities, complemented by strategic collaborations with leading partners.pr@zaiming.com
| Employees | 51 (32 on RocketReach) |
| Founded | 2023 |
| Industry | Pharmaceutical Manufacturing |
Looking for a particular Simcere Zaiming employee's phone or email?
Simcere Zaiming Questions
Tamas Oravecz is the CSO, SVP, Head of Boston Innovation Center of Simcere Zaiming.
32 people are employed at Simcere Zaiming.
Top Simcere Zaiming Employees
-
14
-
Pankaj Seth
Associate Vice President at Simcere Zaiming
Boston, MA, US15 -
Weiss Yang
Assitant vice president at Simcere Zaiming
Shanghai, China2 -
Frank Luo
Head of Business Development, US and Europe at Simcere Zaiming
Washington, DC, US23 -
Pengyu Huang
Head, In Vivo Pharmacology at Simcere Zaiming
Brookline, MA, US21 -
Abdullah al Emran
Senior Scientist at Simcere Zaiming
United States3 -
Nikolaos Patsoukis
Principal Scientist at Simcere Zaiming
Boston, MA, US1
Related Companies
